Immunovant, Inc.: Truist Securities raises target price to $33 from $30
IMVT•Truist Securities raised its target price for Immunovant to $33 from $30.
Related News
Silver Lake prices offering of 15,000,000 First Advantage shares at $21.80 each
FA•
Ultrapar buys back 1,208,800 shares for R$ 42.11 million
UGP•
Gibraltar Industries to present at 18th Annual Southwest IDEAS Conference
ROCK•
Dyadic partners with BRIG BIO, Strive Nutrition to develop precision-fermented alpha-lactalbumin
DYAI•
Venture Global secures $3 billion revolving credit facility
VG•